Two potentially life-extending secondary breast cancer drugs – everolimus (Afinitor) and eribulin (Halaven) – are to remain on the Cancer Drugs Fund (CDF) after an appeal from the pharmaceutical companies that produce them.
The CDF gives patients in England access to drugs that otherwise wouldn't be available through the NHS. The review that led to plans to remove these and other drugs from the...
The General Election is nearly here. Read about our plans to make sure that breast cancer is an election priority.
With the General Election just a few months away, each of the political parties are beginning to make promises about what they...
The Cancer Drugs Fund gives patients in England access to drugs that otherwise wouldn't be available through the NHS.
NHS England today announced that a number of drugs are to be removed from the Cancer Drugs Fund.
Here are eight things you should know about the announcement
- The review of the drugs available on the Cancer Drugs Fund (CDF) is as a result of recent changes to the way the...
- First page
Volunteers Pat and Catherine gave a breast awareness talk at their local doctor’s surgery. Catherine says, 'Pat and I had a great time. I have now started to contact other surgeries to see if they are interested in having a breast awareness talk for their patients. It would be great if we can get the GPs to appreciate what a great asset this could be to their surgeries.'